Answers are grounded in this paper and cite their sources.
The excitatory/inhibitory (E/I) balance is fundamental for proper neural circuit function, and its disruption has emerged as a convergent mechanism across multiple psychiatric disorders. Primarily, GABAergic inhibitory neurons play essential roles in regulating network dynamics, necessary for physiological, cognitive and emotional processing. This review synthesizes current evidence from genetic, epigenetic, transcriptomic, and cellular studies implicating GABAergic neuron dysfunction in autism spectrum disorder (ASD), major depressive disorder (MDD), schizophrenia (SCZ), and bipolar disorder (BD). We first define the E/I balance and its functional implications for neural circuit dynamics and define the main GABAergic subtypes: Parvalbumin (PVALB), Somatostatin (SST), Vasoactive Intestinal Peptide neurons (VIP) and Lysosomal Associated Membrane Protein Family Member 5/Paired Box 6 positive GABAergic neurons (LAMP5/PAX6+). We then examine GABAergic involvement across distinct neurodevelopmental phases, highlighting critical windows of vulnerability where perturbations can produce lasting consequences. Subsequently, we synthesize and discuss disorder-specific evidence across ASD, MDD, SCZ, and BD, which share substantial clinical overlap and converging genetic architectures. High-resolution single-cell and spatial transcriptomic approaches have fundamentally transformed our understanding, revealing that rather than a uniform global deficit, these conditions exhibit localized, cell-type-specific dysregulations that target distinct interneuron subpopulations in a region- and disorder-dependent manner. Methodological advances now enable integration of genomic risk with cell-type-specific transcriptomic and epigenomic profiles, though challenges remain in translating these findings to clinical applications. Despite promising preclinical evidence, clinical trials targeting GABAergic signaling have yielded mixed results, underscoring the complexity of inhibitory circuit dysfunction and the need for more precise, subtype-specific therapeutic strategies. Leveraging these high-resolution, multi-omic insights holds significant promise for refining psychiatric nosology, discovering reliable biomarkers, and advancing targeted therapeutics and personalized medicine.
No takes yet. Share an insight, caveat, or question.
Refundini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: